Baseline characteristics

MENSA BASELINE CHARACTERISTICS1,2

  NUCALA (n=194) Placebo (n=191)
Mean age 51 years 49 years
Female 60% 56%
Body mass index* 27.6 28.0
Duration of asthma 20.5 years 19.5 years
Use of oral glucocorticoids    
   Maintenance use 27% 23%
   Mean daily dose 12.6 mg 15.1 mg
Allergic rhinitis 49% 50%
Nasal polyposis 14% 17%
FEV1    
   Before bronchodilation 1.73 L 1.86 L
   Predicted value before bronchodilation§ 59.3% 62.4%
   Reversibility 27.9% 27.4%
FEV1/FVC ratio 63% 64%
ACQ-5 score|| 2.26 2.28
SGRQ score 47.9 46.9
Geometric mean IgE on loge scale 150 U/mL 150 U/mL
Geometric mean blood eosinophil count on loge scale 290 cells/μL 320 cells/μL
Asthma exacerbations    
   Severe episodes in previous year 3.8 3.6
   Necessitating hospitalization in the previous year 17% 18%
 
 
  •  *Body mass index is the weight in kilograms divided by the square of the height in meters.
  •  The listed value is the prednisone equivalent.
  •  Reversibility was measured at baseline.
  •  §The percent of predicted value before bronchodilation was assessed at the screening visit.
  •  llScores on the ACQ range from 0 to 6 with higher scores indicating worse control; a change of 0.5 points is the minimal clinically important difference.3
  •  Scores on the SGRQ range from 0 to 100 with higher scores indicating worse function; a change of 4 points is considered to be clinically relevant.4,5
  •  
  •   ACQ=Asthma Control Questionnaire; FEV1=forced expiratory volume in 1 second; FVC=forced vital capacity;
  •   IgE=immunoglobulin E; IV=intravenous; SGRQ=St. George’s Respiratory Questionnaire.